dc.date.accessioned2019-04-24T18:23:57Z
dc.date.available2019-04-24T18:23:57Z
dc.date.created2019-04-24T18:23:57Z
dc.date.issued2015
dc.identifierhttps://hdl.handle.net/20.500.12866/6495
dc.identifierhttps://doi.org/10.1590/0037-8682-0148-2015
dc.description.abstractIntroduction: The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica, involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the efficacy and tolerability of 2 schemes of TCBZ. Methods: Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of efficacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment. Results: A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic. Conclusions: The tested scheme was efficacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting.
dc.languageeng
dc.publisherSociedade Brasileira de Medicina Tropical
dc.relationRevista da Sociedade Brasileira de Medicina Tropical
dc.relation1678-9849
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecttriclabendazole
dc.subjectanthelmintic agent
dc.subjectbenzimidazole derivative
dc.subjecttriclabendazole
dc.subjectabdominal pain
dc.subjectanorexia
dc.subjectArticle
dc.subjectbiliary colic
dc.subjectchild
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectenzyme linked immunosorbent assay
dc.subjectepigastric pain
dc.subjectFasciola hepatica
dc.subjectfascioliasis
dc.subjectfeces analysis
dc.subjectfemale
dc.subjectheadache
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectnausea and vomiting
dc.subjectnonhuman
dc.subjectPeru
dc.subjectphase 2 clinical trial
dc.subjectsingle drug dose
dc.subjecttreatment outcome
dc.subjectadolescent
dc.subjectanimal
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectdrug administration
dc.subjectfascioliasis
dc.subjectfeces
dc.subjectparasite identification
dc.subjectparasitology
dc.subjectpreschool child
dc.subjectseverity of illness index
dc.subjectFasciola hepatica
dc.subjectAdolescent
dc.subjectAnimals
dc.subjectAnthelmintics
dc.subjectBenzimidazoles
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectClinical Protocols
dc.subjectDrug Administration Schedule
dc.subjectFasciola hepatica
dc.subjectFascioliasis
dc.subjectFeces
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectParasite Egg Count
dc.subjectPeru
dc.subjectSeverity of Illness Index
dc.titleEfficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución